Bio-Rad Laboratories, Inc. (FRA:BUWA)

Germany flag Germany · Delayed Price · Currency is EUR
277.20
-1.30 (-0.47%)
Last updated: Dec 1, 2025, 8:05 AM CET
-12.64%
Market Cap7.41B
Revenue (ttm)2.18B
Net Income (ttm)-576.07M
Shares Outn/a
EPS (ttm)-20.93
PE Ration/a
Forward PE30.40
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open277.20
Previous Close278.50
Day's Range277.20 - 277.20
52-Week Range187.35 - 349.10
Betan/a
RSI53.75
Earnings DateFeb 13, 2026

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science e... [Read more]

Industry Laboratory Analytical Instruments
Founded 1952
Employees 7,700
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BUWA
Full Company Profile

Financial Performance

In 2024, Bio-Rad Laboratories's revenue was $2.57 billion, a decrease of -3.92% compared to the previous year's $2.67 billion. Losses were -$1.84 billion, 189.4% more than in 2023.

Financial numbers in USD Financial Statements

News

Citigroup Raises Price Target for Bio-Rad Laboratories (BIO) to $375 | BIO Stock News

Citigroup Raises Price Target for Bio-Rad Laboratories (BIO) to $375 | BIO Stock News

4 weeks ago - GuruFocus

Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday

The company doesn't seem like it will generate pops in key fundamentals anytime soon.

4 weeks ago - The Motley Fool

Bio-Rad Laboratories Inc (BIO) Q3 2025 Earnings Call Highlights: Navigating Challenges with ...

Bio-Rad Laboratories Inc (BIO) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives

4 weeks ago - GuruFocus

Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Laboratories Inc (BIO)

Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Laboratories Inc (BIO)

4 weeks ago - GuruFocus

Bio-Rad Laboratories Inc (BIO) Q3 Earnings: Revenue Surpasses Estimates at $653M, Non-GAAP EPS ...

Bio-Rad Laboratories Inc (BIO) Q3 Earnings: Revenue Surpasses Estimates at $653M, Non-GAAP EPS Falls Short at $2.26

4 weeks ago - GuruFocus

Bio-Rad Reports Third-Quarter 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...

4 weeks ago - Business Wire

What to Expect from Bio-Rad Laboratories Inc (BIO) Q3 2025 Earnings

What to Expect from Bio-Rad Laboratories Inc (BIO) Q3 2025 Earnings

4 weeks ago - GuruFocus

Compelling Value In Small-Cap Equities And Select Cyclicals

Supplier of residential thermal, comfort and security solutions, Resideo Technologies, Inc. (REZI) was the top contributor in the quarter. Shares of gold mining company, Barrick Mining Corporation (B)...

5 weeks ago - Seeking Alpha

7 Stocks Taking The Next Step To Be On Offense

Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens ...

5 weeks ago - Seeking Alpha

Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays

Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX...

5 weeks ago - Wallstreet:Online

It's time to scoop up undervalued stocks in this critical sector of the economy

Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.

5 weeks ago - Market Watch

Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...

6 weeks ago - Business Wire

Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.

PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidi...

3 months ago - GlobeNewsWire

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Bio-Rad Laboratories, Inc. (NYSE:BIO) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chai...

3 months ago - Seeking Alpha

Bio-Rad's Management to Participate in Upcoming Investor Conferences

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the com...

3 months ago - Business Wire

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth fo...

4 months ago - Seeking Alpha

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.

4 months ago - Benzinga

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's mana...

4 months ago - Business Wire

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Jonathan P. DiVincenzo - President & COO Norman D.

4 months ago - Seeking Alpha

Bio-Rad Reports Second-Quarter 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...

4 months ago - Business Wire

Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Raja...

4 months ago - Business Wire

Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...

4 months ago - Business Wire